29.20
-0.25 (-0.85%)
| 前收盘价格 | 29.45 |
| 成交量 | 4,365,750 |
| 平均成交量 (3个月) | 2,762,359 |
| 市值 | 5,942,986,752 |
| 价格/销量 (P/S) | 1.94 |
| 股市价格/股市净资产 (P/B) | 1.59 |
| 52周波幅 | |
| 利润日期 | 29 Oct 2026 |
| 股息率 (DY TTM) | 27.84% |
| 营业毛利率 | 32.75% |
| 营业利益率 (TTM) | 46.94% |
| 稀释每股收益 (EPS TTM) | -0.760 |
| 季度收入增长率 (YOY) | 13.40% |
| 季度盈利增长率 (YOY) | 226.20% |
| 总债务/股东权益 (D/E MRQ) | 3.13% |
| 流动比率 (MRQ) | 0.620 |
| 营业现金流 (OCF TTM) | 96.00 M |
| 杠杆自由现金流 (LFCF TTM) | 227.12 M |
| 资产报酬率 (ROA TTM) | 29.34% |
| 股东权益报酬率 (ROE TTM) | 6.32% |
新闻情绪
AIStockmoo 评分
| 价值 38% | 0.0 |
| 负债低。盈利能力强。短期流动性偏紧。现金流为正。 参考 | |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 资本回报 参考 | NA |
| 盈利趋势 参考 | NA |
| 持仓估值 参考 | NA |
| 风险溢价 参考 | NA |
| 市场估值 参考 | NA |
| 时机 38% | -2.7 |
| 过去一年没有明确趋势。股价远低于52周高点。 参考 | |
| 下降趋势:股价位于均线之下,均线向下。股价接近均线。 参考 | |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| K线形态 参考 | NA |
| 市场情绪 25% | 0.7 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 近期新闻大多正面。 参考 | |
| 持仓情绪 参考 | NA |
| 聪明钱 | NA |
| 内部交易活动 参考 | NA |
| 机构资金流 参考 | NA |
| 空头持仓 参考 | NA |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现优于大市。 | |
| 各支柱方向一致,评分因此加强。 | |
| 不计入评分 | |
| 低于中期趋势线。 参考 | |
| 股价低于其52周平均水平。5年来上涨。 参考 | |
| 短、中、长期趋势均向下。短期动能下降。 参考 | |
| 股价接近阻力位。 参考 | |
| 最终评分 | -0.96 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 混合的 | |
| 股票 | Supernus, Inc. | 混合的 | 看涨 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B | 评分 |
|---|---|---|---|---|---|
| SUPN | 6 B | 27.84% | - | 1.59 | -1.0 |
| ANIP | 2 B | - | 13.74 | 2.57 | -0.1 |
| COLL | 783 M | - | 23.13 | 2.72 | 0.1 |
| TKNO | 480 M | - | - | - | 0.8 |
| AQST | 435 M | - | - | - | -1.7 |
| TLRY | 279 M | - | - | 0.200 | -2.2 |
|
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Value |
| 内部持股比例 | 2.06% |
| 机构持股比例 | 61.81% |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 10 Nov 2026 | Yahoo Finance |
Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London
ROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus, Inc., will… |
| 10 Nov 2026 | Yahoo Finance |
Supernus (SUPN) Stock Still Looks Undervalued As Its 127% 5 Year Run Continues
Supernus has had a volatile few years, and with the share price at US$27.62 after a sharp pullback, the key issue is whether that price still lines up with what its earnings can reasonably support. Over the past 5 years, Supernus has delivered a 127.5% share price gain. This puts real weight on the… |
| 09 Nov 2026 | Yahoo Finance |
Supernus undervalued after Indivior merger, says Bank of America
Bank of America has initiated coverage of Supernus Pharmaceuticals (NASDAQ:SUPN) with a 'buy' rating and a $47 price target, arguing that its merger with Indivior creates a larger business with stronger earnings potential. The combined group has a broader portfolio of treatments for nervous… |
| 04 Nov 2026 | Yahoo Finance |
Supernus Pharmaceuticals (SUPN) After Its Indivior Merger Looks Undervalued
Supernus Pharmaceuticals (SUPN) just completed its all‑stock merger with Indivior Pharmaceuticals, creating Supernus, Inc., and simultaneously requested delisting of its legacy shares after multiple index removals connected to the transaction. Recent trading tells a mixed story for Supernus… |
| 03 Nov 2026 | Yahoo Finance |
Supernus Pharmaceuticals (SUPN) Stock May Be Undervalued After ONAPGO Exclusivity
Supernus Pharmaceuticals has had a mixed share price journey, with the stock up strongly over three years but weaker over the past year. That puts fresh attention on what investors are paying for its current level of sales. With new products, a merger closing and a changing revenue mix all in play… |
| 03 Nov 2026 | Yahoo Finance |
What Changes For Supernus Pharmaceuticals (SUPN) After Its Nasdaq Delisting And Merger?
Supernus Pharmaceuticals (NasdaqGM:SUPN) has completed its merger of equals with Indivior Pharmaceuticals, forming a combined specialty pharma business. As part of the transaction, Supernus shares have been delisted from Nasdaq, with equity now rolling into the new merged entity. The deal includes… |
| 02 Nov 2026 | Yahoo Finance |
Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader
Merger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flexibility and a differentiated pipelineSignificantly enhances cash flow profile and scale, unlocking greater capacity to… |
| 02 Nov 2026 | Yahoo Finance |
Why Indivior Pharmaceuticals Stock Topped the Market Today
The company is merging with a peer. |
| 31 Oct 2026 | Yahoo Finance |
SUPN Q3 deep dive: robust portfolio growth and integration priorities amid Indivior merger
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) announced better-than-expected revenue in Q3 2026, with sales up 18.1% year on year to $226.8 million. The company’s full-year revenue guidance of $887.5 million at the midpoint came in 1.5% above analysts’ estimates. Its… |
| 30 Oct 2026 | Yahoo Finance |
Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Turnaround Narrative
Indivior Pharmaceuticals (INDV) moved back into focus after reporting record third quarter earnings and reaffirming its 2026 revenue outlook. This gave investors fresh numbers to weigh alongside an approved merger with Supernus Pharmaceuticals. Over the past year Indivior Pharmaceuticals has… |
| 30 Oct 2026 | Yahoo Finance |
Supernus Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
Moby summary of Supernus Pharmaceuticals, Inc.'s Q3 2026 earnings call… |
| 30 Oct 2026 | Yahoo Finance |
Supernus (SUPN) Q3 2026 Earnings Call Transcript
Qelbree prescriptions surged 18% as revenue hit $226.8 million ahead of Indivior merger. |
| 30 Oct 2026 | Yahoo Finance |
Indivior Pharmaceuticals (INDV) Shareholders Back Merger After Record Third Quarter
Indivior Pharmaceuticals (NasdaqGS: INDV) reported record third quarter results, highlighting its strongest Q3 performance to date. Shareholders approved a merger with Supernus Pharmaceuticals that will see the combined business operate under the Supernus brand. The transaction is expected to close… |
| 29 Oct 2026 | Yahoo Finance |
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +89.80% and +1.39%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 29 Oct 2026 | Yahoo Finance |
Supernus Pharmaceuticals Q3 Earnings Call Highlights
Supernus Pharmaceuticals (NASDAQ:SUPN) reported record third-quarter revenue and higher sales across its growth portfolio, while management said its planned merger with Indivior Pharmaceuticals is expected to close Nov. 2 following shareholder approvals. Total revenue rose 18% year over year to $22… |
| 29 Oct 2026 | Yahoo Finance |
Supernus: Q3 Earnings Snapshot
(AP) — Supernus Pharmaceuticals Inc. (SUPN) on Thursday reported profit of $20… |
| 29 Oct 2026 | Yahoo Finance |
Supernus Pharmaceuticals (NASDAQ:SUPN) delivers impressive Q3 2026, full-year sales guidance is optimistic
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) beat Wall Street’s revenue expectations in Q3 2026, with revenue rising 18.1% year on year to $226.8 million. The company’s full-year revenue guidance of $887.5 million at the midpoint came in 1.5% above analysts’ consensus… |
| 29 Oct 2026 | Yahoo Finance |
Supernus Announces Third Quarter 2026 Financial Results
Record total revenues of $226.8 million in the third quarter 2026, an 18% increase compared to same period last year.Combined revenues of the Company's four growth products increased to $192.2 million in the third quarter 2026, representing an increase of 29% compared to the same period last year.… |
| 显示更多 | ||
| 股息率 (DY TTM) | 27.84% |
| 预计下次股息支付 | Nov 2027 |
| 除息日 | 公告日期 | 支付日期 | 详情 |
|---|---|---|---|
| 03 Nov 2026 | 16 Sep 2026 | 06 Nov 2026 | 8.13 现金 |
每年股息收益率
| 年份 | 每年总股息 ($) | 频率/年份 | 收益率 % |
|---|---|---|---|
| 2026 | 8.13 | 1 | 27.84 |
近期信号 K线形态与EMA交叉
技术形态 中期
AI 技术分析
投资组合